Quality of advanced ovarian cancer surgery: A French assessment of ESGO quality indicators

Author(s):  
Marie-Mélanie Gac ◽  
Cécile Loaec ◽  
Johanna Silve ◽  
Edouard Vaucel ◽  
Paule Augereau ◽  
...  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Antoni Llueca ◽  
◽  
Anna Serra ◽  
Maria Teresa Climent ◽  
Blanca Segarra ◽  
...  

Abstract Introduction Advanced ovarian cancer surgery (AOCS) frequently results in serious postoperative complications. Because managing AOCS is difficult, some standards need to be established that allow surgeons to assess the quality of treatment provided and consider what aspects should improve. This study aimed to identify quality indicators (QIs) of clinical relevance and to establish their acceptable quality limits (i.e., standard) in AOCS. Materials and methods We performed a systematic search on clinical practice guidelines, consensus conferences, and reviews on the outcome and quality of AOCS to identify which QIs have clinical relevance in AOCS. We then searched the literature (from January 2006 to December 2018) for each QI in combination with the keywords of advanced ovarian cancer, surgery, outcome, and oncology. Standards for each QI were determined by statistical process control techniques. The acceptable quality limits for each QI were defined as being within the limits of the 99.8% interval, which indicated a favorable outcome. Results A total of 38 studies were included. The QIs selected for AOCS were complete removal of the tumor upon visual inspection (complete cytoreductive surgery), a residual tumor of < 1 cm (optimal cytoreductive surgery), a residual tumor of > 1 cm (suboptimal cytoreductive surgery), major morbidity, and 5-year survival. The rates of complete cytoreductive surgery, optimal cytoreductive surgery, suboptimal cytoreductive surgery, morbidity, and 5-year survival had quality limits of < 27%, < 23%, > 39%, > 33%, and < 27%, respectively. Conclusion Our results provide a general view of clinical indicators for AOCS. Acceptable quality limits that can be considered as standards were established.


2016 ◽  
Vol 26 (7) ◽  
pp. 1354-1363 ◽  
Author(s):  
Denis Querleu ◽  
François Planchamp ◽  
Luis Chiva ◽  
Christina Fotopoulou ◽  
Desmond Barton ◽  
...  

2019 ◽  
Vol 35 (S1) ◽  
pp. 97-97
Author(s):  
Carole Cummins ◽  
Hannah Patrick ◽  
Joanna Long ◽  
Satyam Kumar ◽  
Sudha Sundar ◽  
...  

IntroductionOvarian Cancer is usually diagnosed at an advanced stage. Extensive or ultra-radical surgery aims to improve the outcome by removing all visible tumour. National Institute for Health and Care Excellence UK 2013 Guidance expressed concern about its efficacy and safety, recommending research comparing complication rates, survival and quality of life with those following standard surgery. We present prospective observational data on quality of life and survival following surgery for advanced ovarian cancer. Innovative methods were used to collect patient reported outcomes and complex surgical information to compare outcomes of surgery of greater or lesser complexity used in routine practice.MethodsA cohort study collected disease, surgical, complications, survival and quality of life data (validated instruments including EURO-QOL, EORTC-30 and OVA28) across a 2-year period in 12 United Kingdom sites and in parallel studies in Melbourne, Australia and Kolkata, India.ResultsTwo hundred and sixty patients undergoing cytoreductive surgery were recruited in 12 months. Centres varied in utilisation of complex surgical procedures. Excluding patients with inoperable disease, 125 patients underwent low, 70 intermediate and 63 high Surgical Complexity Score (SCS) procedures. Complete cytoreduction with < 1cm residual disease was achieved in 100/125 (80 percent) low, 65/70 (92 percent) intermediate, and 57/63 (90 percent) high SCS groups (p = 0.023). Compliance with 12 months questionnaires was 89%. All surgical groups had improved EORTC QLC 30 Global at 12 months compared with prior to operation, with overlapping 95% confidence intervals and no between group differences at 12 months. Complications, survival and quality of life adjusted for disease burden and surgical complexity over 2 years’ follow-up will be described.ConclusionsResults will inform the update of NICE Interventional Procedures guidance recommendations on clinical governance arrangements for ovarian cancer surgery and enable clinicians and patients to better understand the outcomes of surgery, informing the consent process.


2020 ◽  
Vol 30 (4) ◽  
pp. 436-440 ◽  
Author(s):  
Christina Fotopoulou ◽  
Nicole Concin ◽  
François Planchamp ◽  
Philippe Morice ◽  
Ignace Vergote ◽  
...  

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Antoni Llueca ◽  
◽  
Anna Serra ◽  
Maria Teresa Climent ◽  
Blanca Segarra ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


2001 ◽  
Vol 19 (5) ◽  
pp. 1266-1274 ◽  
Author(s):  
Catherine Doyle ◽  
Michael Crump ◽  
Melania Pintilie ◽  
Amit M. Oza

PURPOSE: The value of palliative chemotherapy in women with refractory and recurrent ovarian cancer is difficult to quantify, and little is known about patient expectations from these treatments. We evaluated in the current prospective study patient expectations, palliative outcomes of chemotherapy, and the inherent resource utilization in patients undergoing second- or third-line chemotherapy for recurrent or refractory advanced ovarian cancer. METHODS: The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (EORTC QLQ C30) and Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaires were used to assess palliative benefit and an in-house questionnaire was used to gauge patient expectations. The minimal clinically important difference (MCID) was calculated by asking women to make a global rating of change and correlating this to the EORTC QLQ C30. Resource use was recorded and costs were calculated. RESULTS: Twenty-seven patients were accrued. Objective response was documented on seven of 27. The median survival was 11 months. Sixty-five percent of women expected that chemotherapy would make them live longer and 42% that it would cure them. After two cycles, quality-of-life (QL) improvement was seen particularly in global function (11 of 21) and emotional function (13 of 21) with EORTC QLQ C-30. Improvement was sustained for a median of 2 and 3 months, respectively, in these categories. The MCID was calculated to be 0.39 on a seven-point scale for physical function and 0.13 for global function. The mean total cost per patient for the study period was Can $12,500. CONCLUSION: Patient expectations from these treatments are often unrealistic. Although objective responses are low, active palliation with chemotherapy is associated with substantive improvement in patients’ emotional function and global QL, with overall costs that seem relatively modest.


Sign in / Sign up

Export Citation Format

Share Document